(Stockholm, 27 februari 2024) Asarina Pharma (”Bolaget”) publicerar idag sin andra halvårs- och bokslutsrapport för 2023. Den fullständiga rapporten (på engelska) finns tillgänglig på företagets… Read More »ASARINA PHARMA AB (PUBL) SLÄPPER BOKSLUTSKOMMUNIKÉ 2023
(Stockholm, 27 February 2024) Asarina Pharma (“the Company”) today releases its Second Half-Year and Year-End Report for 2023. The full Report (in English) is available… Read More »ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023
Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB. The Company has entered into… Read More »Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB
Bolaget meddelar idag att man byter Certified Adviser från Erik Penser Bank AB till Carnegie Investment Bank AB (publ). Bolaget har ingått avtal med Carnegie… Read More »Asarina Pharma AB byter Certified Adviser till Carnegie Investment Bank AB (publ)
(Stockholm, 23 augusti 2023) Asarina Pharma publicerar idag sin första halvårsrapport för 2023. Utöver de finansiella rapporterna för H1/2023 innehåller rapporten uppdateringar om bolagets kommunikation… Read More »Asarina Pharma AB (publ) släpper rapport för första halvåret (H1/2023)
(Stockholm, 23 August 2023) Asarina Pharma today releases its First Half-Year Report for 2023. In addition to the financial statements for H1/2023, the report includes… Read More »Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in Asarina Pharma’s Phase IIa study in… Read More »Positive Tourette Syndrome results to be presented at ESSTS, 15th European Conference on Tourette Syndrome and Tic Disorders
Asarina Pharma AB (publ) (”Bolaget”) avhöll den 22 maj 2023 årsstämma i Fredersen Advokatbyrås lokaler på Birger Jarlsgatan 8 i Stockholm. Vid stämman fattades bland… Read More »Kommuniké från årsstämma i Asarina Pharma AB (publ)
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on 22 May 2023 at Fredersen… Read More »Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
(Stockholm, 28 April 2023) Asarina Pharma’s 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results for Tourette syndrome, as well… Read More »Asarina Pharma AB (publ) releases Annual Report 2022